FrancophonIA/ELRC3.0 huggingface dataset:
English: Frequency not known: kidney problems (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Danish: Hyppighed ikke kendt: nyreproblemer (som kan kræve dialyse), opkastning, ledsmerter, muskelsmerter, rygsmerter, interstitiel lungesygdom, bulløs pemfigoid (en type blærer på huden).
English: Frequency not known exfoliative skin conditions including Stevens-Johnson syndrome
Danish: Eksfoliative hudsygdomme herunder StevensJohnsons syndrom
English: However, when this medicine is used in combination with a sulphonylurea medicine or with insulin, low blood sugar (hypoglycaemia) can occur.
Danish: Når lægemidlet tages sammen med et sulfonylurinstof eller sammen med insulin, kan lavt blodsukker (hypoglykæmi) forekomme.
English: Some patients have experienced the following side effects while taking sitagliptin in combination with insulin (with or without metformin):
Danish: Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin sammen med insulin (med eller uden metformin):
English: Do not throw away medicines via wastewater or household waste.
Danish: Af hensyn til miljøet må De ikke smide medicinrester i afløbet, toilettet eller skraldespanden.
English: This medicine has no or negligible influence on the ability to drive and use machines.
Danish: Lægemidlet påvirker ikke eller kun i ubetydelig grad evnen til at køre bil eller betjene maskiner.
English: Sitagliptin is primarily eliminated unchanged in urine, and metabolism is a minor pathway.
Danish: Sitagliptin metaboliseres i mindre grad og elimineres primært uændret i urinen.
English: Blood and lymphatic system disorders thrombocytopenia
Danish: Blod og lymfesystem Trombocytopeni
English: The reduction in HbA1c from mean baseline values of 7.2 % was -0.43 % for sitagliptin and -0.57 % for metformin (Per Protocol Analysis).
Danish: Reduktionen i HbA1c i forhold til de gennemsnitlige baselineværdier på 7,2% var -0,43% for sitagliptin og -0,57% for metformin (Per Protocol Analysis).
English: In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin is CYP3A4, with contribution from CYP2C8.
Danish: In vitro-undersøgelser indikerede, at det enzym, der primært er ansvarlig for sitagliptins begrænsede metabolisering, er CYP3A4, med medvirken fra CYP2C8.
English: The incidence of hypoglycaemia in the sitagliptin group (4.9 %) was significantly lower than that in the glipizide group (32.0 %).
Danish: Incidensen af hypoglykæmi i gruppen, som blev behandlet med sitagliptin (4,9%), var signifikant lavere end i glipizidgruppen (32,0%).
English: When Ristaben is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see section 4.4).
Danish: Når Ristaben anvendes i kombination med et sulfonylurinstof eller sammen med insulin, kan en lavere dosis af sulfonylurinstof eller insulin overvejes for at reducere risikoen for hypoglykæmi (se pkt.
English: Compared to normal healthy control subjects, plasma AUC of sitagliptin was increased by approximately 1.2-fold and 1.6-fold in patients with mild renal impairment (GFR ≥ 60 to < 90 mL/min) and patients with moderate renal impairment (GFR ≥ 45 to < 60 mL/min), respectively.
Danish: Sammenlignet med normale raske kontrolpersoner steg sitagliptins plasma-AUC med henholdsvis ca. 1,2 gange og 1,6 gange hos patienter med let nyreinsufficiens (GFR ≥60 til <90 ml/min) og patienter med moderat nyreinsufficiens (GFR ≥45 til <60 ml/min).
English: Some patients have experienced the following side effects while taking sitagliptin alone in clinical studies, or during post-approval use alone and/or with other diabetes medicines: Common: low blood sugar, headache, upper respiratory infection, stuffy or runny nose and sore throat, osteoarthritis, arm or leg pain
Danish: Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin alene i kliniske studier eller ved anvendelse efter markedsføring alene og/eller sammen med anden diabetesmedicin: Almindelige: Lavt blodsukker, hovedpine, infektion i øvre luftveje, stoppet næse eller snue og ondt i halsen, betændelse i led og den tilgrænsede knogle, smerter i arme eller ben.
English: Study
Danish: Undersøgelse
English: Secondary cardiovascular endpoints included the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke; first occurrence of the individual components of the primary composite; all-cause mortality; and hospital admissions for congestive heart failure.
Danish: Sekundære kardiovaskulære endepunkter bestod af første forekomst af kardiovaskulær død, ikke-letalt myokardieinfarkt eller ikke-letal apopleksi samt første forekomst af de enkelte komponenter i det primære sammensatte endepunkt, død uanset årsag og hospitalsindlæggelse på grund af kongestivt hjertesvigt.
English: No dose adjustment for Ristaben is necessary for patients with mild or moderate hepatic impairment (Child-Pugh score  9).
Danish: Dosisjustering af Ristaben er ikke nødvendig hos patienter med mild eller moderat leverinsufficiens (Child-Pugh score ≤9).
English: Respiratory, thoracic and mediastinal disorders interstitial lung disease
Danish: Luftveje, thorax og mediastinum Interstitiel lungesygdom
English: Ristaben has not been studied in patients with severe hepatic impairment and care should be exercised (see section 5.2).
Danish: Ristaben er ikke undersøgt hos patienter med svær leverinsufficiens, og der bør udvises forsigtighed (se pkt.
English: Sitagliptin was modestly removed by haemodialysis (13.5 % over a 3- to 4-hour haemodialysis session starting 4 hours postdose).
Danish: Sitagliptin elimineredes moderat ved hæmodialyse (13,5% over en 3-4 timers hæmodialysesession med start 4 timer efter dosering).
English: For patients with severe renal impairment (GFR ≥ 15 to <30 mL/min) or with end-stage renal disease (ESRD) (GFR < 15 mL/min), including those requiring haemodialysis or peritoneal dialysis, the dose of Ristaben is 25 mg once daily.
Danish: Til patienter med svær nyreinsufficiens (GFR ≥15 til <30 ml/min) eller med nyresygdom i slutstadiet (ESRD) (GFR <15 ml/min), inklusive patienter som har behov for hæmodialyse eller peritonealdialyse, er dosis 25 mg Ristaben en gang dagligt.
English: Ristaben is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.
Danish: Ristaben tilhører en klasse af orale anti-hyperglykæmiske lægemidler, der kaldes dipeptidylpeptidase4-(DPP-4)-hæmmere.
English: • a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.
Danish: • et sulfonylurinstof, når diæt og motion plus maksimal tolereret dosis af et sulfonylurinstof alene ikke giver tilstrækkelig glykæmisk kontrol, og når metformin ikke er hensigtsmæssigt pga. af kontraindikationer eller intolerance.
English: Do not use this medicine after the expiry date which is stated on the blister and the carton after 'EXP'.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned.
English: In a 24-week placebo-controlled factorial study of initial therapy, sitagliptin 50 mg twice daily in combination with metformin (500 mg or 1,000 mg twice daily) provided significant improvements in glycaemic parameters compared with either monotherapy.
Danish: I en 24-ugers placebokontrolleret faktoriel undersøgelse af initialbehandling gav sitagliptin 50 mg to gange dagligt i kombination med metformin (500 mg eller 1.000 mg to gange dagligt) en signifikant glykæmisk forbedring sammenlignet med begge former for monoterapi.
English: After 54 weeks, the mean reduction from baseline in HbA1c was -0.72 % with sitagliptin and -0.87 % with glipizide.
Danish: Efter 54 uger var den gennemsnitlige reduktion i forhold til baseline i HbA1c -0,72% med sitagliptin og -0,87% med glipazid.
English: Effects of other medicinal products on sitagliptin Clinical data described below suggest that the risk for clinically meaningful interactions by co-administered medicinal products is low.
Danish: De kliniske data beskrevet nedenfor tyder på, at risikoen er lav for interaktioner af klinisk betydning mellem lægemidler, der administreres samtidigt.
English: Because increases of this magnitude are not clinically relevant, dosage adjustment in these patients is not necessary.
Danish: Dosisjustering er ikke nødvendig hos disse patienter, da stigninger i denne størrelsesorden ikke er klinisk relevante.
English: A 24-week active (metformin)-controlled study was designed to evaluate the efficacy and safety of sitagliptin 100 mg once daily (N=528) compared to metformin (N=522) in patients with inadequate glycaemic control on diet and exercise and who were not on anti-hyperglycaemic therapy (off therapy for at least 4 months).
Danish: En 24-ugers aktiv (metformin)-kontrolleret undersøgelse blev designet til vurdering af effekt og sikkerhed af sitagliptin 100 mg en gang dagligt (N=528) sammenlignet med metformin (N=522) hos patienter med utilstrækkelig glykæmisk kontrol på diæt og motion, og som ikke var i antihyperglykæmisk behandling (uden behandling i mindst 4 måneder).
English: nausea or vomiting) - any past or present kidney problems.
Danish: - Tidligere eller nuværende nyreproblemer.
English: In a study comparing the efficacy and safety of the addition of sitagliptin 100 mg once daily or glipizide (a sulphonylurea) in patients with inadequate glycaemic control on metformin monotherapy, sitagliptin was similar to glipizide in reducing HbA1c.
Danish: I en undersøgelse af effekt og sikkerhed af tillægsbehandling med sitagliptin 100 mg en gang dagligt eller glipizid (et sulfonylurinstof) til patienter med utilstrækkelig glykæmisk kontrol på metforminmonoterapi, var sitagliptin sammenlignelig med glipizid mht. reduktion af HbA1c.
English: • metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
Danish: • metformin, i de tilfælde hvor diæt og motion plus metformin alene ikke giver tilstrækkelig glykæmisk kontrol.
English: Some patients have experienced the following side effects while taking sitagliptin and pioglitazone: Common: flatulence, swelling of the hands or legs
Danish: Nogle patienter har oplevet følgende bivirkninger, når de har taget sitagliptin og pioglitazon: Almindelige: Øget luftafgang fra tarmen, hævede hænder eller ben.
English: Plasma AUC of sitagliptin was increased approximately 2-fold in patients with moderate renal impairment (GFR ≥ 30 to < 45 mL/min), and approximately 4-fold in patients with severe renal impairment (GFR < 30 mL/min), including in patients with ESRD on haemodialysis.
Danish: Sitagliptins plasma-AUC steg med ca. det dobbelte hos patienter med moderat nyreinsufficiens (GFR ≥30 til <45 ml/min) og med ca. det firdobbelte hos patienter med svær nyreinsufficiens (GFR <30 ml/min), inklusive patienter med ESRD i hæmodialyse.
English: In addition, after 12 weeks, the mean reductions in HbA1c (sitagliptin -0.59 %; placebo -0.18 %) and FPG (sitagliptin -25.5 mg/dL; placebo -3.0 mg/dL) were generally similar to those observed in other monotherapy studies in patients with normal renal function (see section 5.2).
Danish: Desuden var den gennemsnitlige reduktion i HbA1c (sitagliptin -0,59%; placebo -0,18%) efter 12 uger og FPG (sitagliptin -25,5 mg/dl; placebo -3,0 mg/dl) generelt de samme som i andre monoterapiundersøgelser hos patienter med normal nyrefunktion (se pkt.
English: In addition to the drug-related adverse experiences described above, adverse experiences reported regardless of causal relationship to medication and occurring in at least 5 % and more commonly in patients treated with sitagliptin included upper respiratory tract infection and nasopharyngitis.
Danish: Ud over de lægemiddelrelaterede bivirkninger, der er beskrevet ovenfor, var øvre luftvejsinfektioner og nasopharyngitis medtaget under de bivirkninger, som blev rapporteret uden hensyntagen til årsagssammenhæng med lægemidlet og som forekom hos mindst 5% og hyppigst hos de patienter, som var i behandling med sitagliptin.
English: If bullous pemphigoid is suspected, Ristaben should be discontinued.
Danish: Hvis der er mistanke om bulløs pemfigoid, skal Ristaben seponeres.
English: - The other ingredients are: In the tablet core: microcrystalline cellulose (E460), calcium hydrogen phosphate, anhydrous (E341), croscarmellose sodium (E468), magnesium stearate (E470b), and sodium stearyl fumarate.
Danish: - Øvrige indholdsstoffer: I tabletkernen: Mikrokrystallinsk cellulose (E460), calciumhydrogenphosphat, vandfrit (E341), croscarmellosenatrium (E468), magnesiumstearat (E470b) og natriumstearylfumarat.
English: Pharmacotherapeutic group: Drugs used in diabetes, Dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code: A10BH01.
Danish: Dipeptidylpeptidase-4-(DPP-4-)-hæmmer, ATCkode: A10BH01.
English: No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
Danish: Dosisjustering er ikke nødvendig til patienter med mild til moderat leverinsufficiens.
English: By enhancing active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in a glucose-dependent manner.
Danish: Ved at øge de aktive inkretinniveauer øger sitagliptin insulinfrigørelsen og reducerer glucagonniveauer afhængigt af glucosekoncentrationen.
English: The addition of sitagliptin to either glimepiride alone or to glimepiride and metformin provided significant improvements in glycaemic parameters.
Danish: Supplering af sitagliptin til enten glimepirid alene eller til glimepirid og metformin gav signifikant glykæmiske forbedringer.
English: Renal and urinary disorders impaired renal function
Danish: Nyrer og urinveje Nedsat nyrefunktion
English: The incidence of adjudication-confirmed pancreatitis events was 0.3 % in sitagliptin-treated patients and 0.2 % in placebo-treated patients.
Danish: Incidensen af bekræftede tilfælde af pankreatitis var 0,3% i sitagliptin-armen og 0,2% i placebo-armen.
English: The tablet film coating contains: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), red iron oxide (E172), and yellow iron oxide (E172).
Danish: Filmovertrækket indeholder: Poly(vinylalkohol), macrogol 3350, talcum (E553b), titandioxid (E171), rød jernoxid (E172) og gul jernoxid (E172).
English: In this study, the efficacy and safety profile of sitagliptin at 25 mg once daily was generally similar to that observed in other monotherapy studies in patients with normal renal function.
Danish: I denne undersøgelse var virknings- og sikkerhedsprofilen for sitagliptin 25 mg en gang dagligt generelt den samme som i andre monoterapiundersøgelser hos patienter med normal nyrefunktion.
English: The Trial Evaluating Cardiovascular Outcomes with sitagliptin (TECOS) included 7,332 patients treated with sitagliptin, 100 mg daily (or 50 mg daily if the baseline eGFR was ≥ 30 and < 50 mL/min/1.73 m2), and 7,339 patients treated with placebo in the intention-to-treat population.
Danish: TECOS-studiet (The Trial Evaluating Cardiovascular Outcomes with Sitagliptin) inkluderede 7.332 patienter, som blev behandlet med sitagliptin 100 mg dagligt (eller 50 mg dagligt, hvis eGFR ved baseline var ≥ 30 og < 50 ml/min/1,73 m2), og 7.339 patienter, som fik placebo, i intention to treat-populationen.
English: With higher insulin levels, tissue glucose uptake is enhanced.
Danish: Med højere insulinniveauer fremmes glucoseoptagelsen i vævet.
English: Transient treatment-related physical signs, some of which suggest neural toxicity, such as open-mouth breathing, salivation, white foamy emesis, ataxia, trembling, decreased activity, and/or hunched posture were observed in dogs at exposure levels approximately
Danish: Nogle af disse tyder på neural toksicitet: Vejrtrækning med åben mund, spytafsondring, hvid skummende opkastning, ataksi, skælven, nedsat aktivitet og/eller krum stilling.
English: No adverse effects upon fertility were observed in male and female rats given sitagliptin prior to and throughout mating.
Danish: Der blev ikke observeret bivirkninger i fertiliteten hos han- og hunrotter, der blev behandlet med sitagliptin før og under parringsperioden.
English: Mean baseline HbA1c (%)
Danish: Gennemsnitlig baseline HbA1c (%)
English: Uncommon: dizziness, constipation, itching
Danish: Ikke almindelige: Svimmelhed, forstoppelse, kløe.
English: • a PPAR agonist and metformin when use of a PPAR agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
Danish: • en PPAR-agonist og metformin, når anvendelse af en PPAR-agonist er hensigtsmæssig, og når diæt og motion plus dual behandling med disse lægemidler ikke giver tilstrækkelig glykæmisk kontrol.
English: HbA1c (%) at week 18.
Danish: HbA1c (%) i 18. uge
English: After 54 weeks, the mean reduction from baseline in HbA1c was -0.76 % with sitagliptin and -0.64 % with glipizide (Per-Protocol Analysis).
Danish: Efter 54 uger var den gennemsnitlige reduktion i forhold til baseline i HbA1c -0,76% med sitagliptin og -0,64% med glipizid (Per Protocol Analysis).
English: Sitagliptin has not been demonstrated to be genotoxic in preclinical studies.
Danish: Prækliniske undersøgelser har ikke vist, at sitagliptin er genotoksisk.
English: Do not take a double dose of this medicine.
Danish: De må ikke tage en dobbeltdosis som erstatning for den glemte dosis af lægemidlet.
English: For patients with moderate renal impairment (GFR  30 to < 45 mL/min), the dose of Ristaben is 50 mg once daily.
Danish: Til patienter med moderat nyreinsufficiens (GFR ≥30 til <45 ml/min) er dosis 50 mg Ristaben en gang dagligt.
English: All stroke (fatal and non-fatal)
Danish: Alle tilfælde af apopleksi (letale og ikke-letale)
English: The primary cardiovascular endpoint was a composite of the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina.
Danish: Det primære kardiovaskulære endepunkt var sammensat af første forekomst af kardiovaskulær død, ikke-letalt myokardieinfarkt, ikke-letal apopleksi eller hospitalsindlæggelse på grund af ustabil angina.
English: Tablet core: microcrystalline cellulose (E460) calcium hydrogen phosphate, anhydrous (E341) croscarmellose sodium (E468) magnesium stearate (E470b) sodium stearyl fumarate
Danish: Mikrokrystallinsk cellulose (E460) Calciumhydrogenphosphat, vandfrit (E341) Croscarmellosenatrium (E468) Magnesiumstearat (E470b) Natriumstearylfumarat
English: Frequency of adverse reaction
Danish: Bivirkningsfrekvens
English: In this study, the efficacy and safety profile of sitagliptin at 25 or 50 mg once daily was generally similar to that observed in other monotherapy studies in patients with normal renal function.
Danish: I denne undersøgelse var virkningsog sikkerhedsprofilen for sitagliptin 25 eller 50 mg en gang dagligt generelt den samme som i andre monoterapiundersøgelser hos patienter med normal nyrefunktion.
English: Additional adverse experiences reported regardless of causal relationship to medication that occurred more frequently in patients treated with sitagliptin (not reaching the 5 % level, but occurring with an incidence of > 0.5 % higher with sitagliptin than that in the control group) included osteoarthritis and pain in extremity.
Danish: Derudover var osteoartritis og ekstremitetssmerter medtaget under de bivirkninger, som blev rapporteret uden hensyntagen til årsagssammenhæng med lægemidlet og som forekom hyppigere hos patienter i behandling med sitagliptin (som ikke nåede niveauet på 5%, men som forekom med en incidens, der var > 0,5% højere med sitagliptin i forhold til incidensen i kontrolgruppen).
English: In these studies there was a similar incidence of hypoglycaemia reported for patients treated with sitagliptin or placebo.
Danish: I disse undersøgelser var incidensen af hypoglykæmi den samme, som blev rapporteret for patienter, der var blevet behandlet med sitagliptin eller placebo.
English: Patients treated with sitagliptin had a modest increase in body weight compared to those given placebo.
Danish: Patienter, der blev behandlet med sitagliptin havde en moderat vægtøgning sammenlignet med de patienter, der fik placebo.
English: Body weight did not increase from baseline with sitagliptin therapy in either study, compared to a small reduction in patients given placebo.
Danish: I undersøgelserne blev kropsvægten ikke øget fra baseline ved behandling med sitagliptin, mens der sås en lille vægtreduktion hos patienter, der fik placebo.
English: HbA1c (%) at week 26.
Danish: HbA1c (%) i 26. uge
English: For patients with mild renal impairment (glomerular filtration rate [GFR]  60 to < 90 ml/min), no dose adjustment is required.
Danish: Til patienter med let nyreinsufficiens (glomerulær filtrationsrate [GFR] 60 til <90 ml/min) er dosisjustering ikke nødvendig.
English: Change from baseline in body weight was similar for patients treated with sitagliptin relative to placebo.
Danish: Ændringen i kropsvægt i forhold til baseline var den samme for patienter, der blev behandlet med sitagliptin i forhold til placebo.
English: For patients with moderate renal impairment (GFR  45 to < 60 mL/min), no dosage adjustment is required.
Danish: Til patienter med moderat nyreinsufficiens (GFR 45 til <60 ml/min) er dosisjustering ikke nødvendig.
English: Tell your doctor if you have or have had: - a disease of the pancreas (such as pancreatitis) - gallstones, alcohol dependence or very high levels of triglycerides (a form of fat) in your blood.
Danish: Fortæl Deres læge, om De har eller har haft: - En sygdom i bugspytkirtlen (f.eks. pankreatitis).
English: A no-effect level for these findings was found at an exposure 6-fold the clinical exposure level.
Danish: Tilsvarende forandringer var ikke til stede ved en eksponering, der var 6 gange højere end den kliniske eksponering.
English: HbA1c (%) at week 24.
Danish: HbA1c (%) i 24. uge
English: Frequency not known fatal and non-fatal haemorrhagic and necrotizing pancreatitis
Danish: Letal og ikke-letal hæmoragisk og nekrotiserende pankreatitis
English: Treatment with sitagliptin at 100 mg once daily as monotherapy provided significant improvements in HbA1c, fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hour PPG), compared to placebo in two studies, one of 18- and one of 24-weeks duration.
Danish: Behandling med sitagliptin 100 mg en gang dagligt som monoterapi gav signifikante forbedringer i HbA1c, i faste-plasma-glucose (FPG) og i 2-timers postprandial glucose (2-timers PPG), når det blev sammenlignet med placebo i to undersøgelser, hvoraf den ene var af 18 ugers varighed og den anden af 24 ugers varighed.
English: The observed incidence of hypoglycaemia in patients treated with sitagliptin was similar to placebo.
Danish: Den observerede incidens af hypoglykæmi hos de patienter, der blev behandlet med sitagliptin, var den samme som for placebo.
English: The reduction in HbA1c in patients treated with sitagliptin and insulin (with or without metformin) was -1.31 % compared to -0.87 % in patients treated with placebo and insulin (with or without metformin), a difference of -0.45 % [95 % CI: -0.60, -0.29].
Danish: Reduktionen i HbA1c hos de patienter, der blev behandlet med sitagliptin og insulin (med eller uden metformin), var -1,31% sammenlignet med -0,87% hos de patienter, der blev behandlet med placebo og insulin (med eller uden metformin), en forskel på -0,45% [95% konfidensinterval: -0,60; -0,29].
English: Mean change from baseline HbA1c (%)
Danish: Gennemsnitlig ændring fra baseline HbA1c (%)
English: The usual recommended dose is: one 100mg film-coated tablet once a day by mouth
Danish: Den almindelige anbefalede dosis er: - En 100 mg filmovertrukken tablet.
English: The addition of sitagliptin to pioglitazone and metformin provided significant improvements in glycaemic parameters.
Danish: Sitagliptin som supplement til pioglitazon og metformin forbedrede de glykæmiske parametre signifikant.